Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - benzatropine mesilate, quantity: 1 mg/ml - injection - excipient ingredients: sodium chloride; water for injections - benzatropine injection is recommended for all forms of parkinsonism - including arteriosclerotic, post-encephalitic, idiopathic, as well as drug induced extrapyramidal disorders (except tardive dyskinesia). it can be effective at any stage of the disease, even when a patient has become bedridden. benzatropine injection often is helpful in patients who have become unresponsive to other agents. benzatropine injection is a powerful antichlolinergic agent which is mainly effective in relieving tremor and rigidity. therapy is directed toward control of disturbing symptoms to permit the patient maximum integration of function with minimum discomfort. in non-drug-induced parkinsonism, partial control of symptoms is usually achieved.

Singapore - English - HSA (Health Sciences Authority)

phebra (se asia) pte. ltd. - benzatropine mesilate - injection, solution - benzatropine mesilate 2.0 mg/2ml

New Zealand - English - Medsafe (Medicines Safety Authority)

phebra nz limited - benzatropine mesilate 1 mg/ml - solution for injection - 2 mg/2ml - active: benzatropine mesilate 1 mg/ml excipient: sodium chloride water for injection - benzatropine injection is recommended for all forms of parkinsonism including arteriosclerotic, post-encephalitic, idiopathic, as well as medicine-induced extrapyramidal disorders (except tardive dyskinesia). it can be effective at any stage of the disease, even when a patient has become bedridden. benzatropine injection often is helpful in patients who have become unresponsive to other agents. benzatropine injection is a powerful anticholinergic agent which is mainly effective in relieving tremor and rigidity. therapy is directed toward control of disturbing symptoms to permit the patient maximum integration of function with minimum discomfort. in non-medicine-induced parkinsonism, partial control of symptoms is usually achieved.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - benzatropine mesilate, quantity: 2 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; microcrystalline cellulose; magnesium stearate - indicated for the treatment of all forms of parkinsonism. the treatment of extrapyramidal reactions (except tardive dyskinesia [see contraindications and precautions]) due to neuroleptic drugs.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - benzatropine mesilate - oral solution - 200microgram/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - benzatropine mesilate - oral tablet - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - benzatropine mesilate - oral tablet - 1mg

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - benzatropine mesilate 2mg - tablet - 2 mg - active: benzatropine mesilate 2mg excipient: lactose magnesium stearate microcrystalline cellulose pregelatinised maize starch - benztrop tablets are indicated for the treatment of all forms of parkinsonism and the treatment of extrapyramidal reactions (except tardive dyskinesia) due to neuroleptic drugs.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - benzatropine mesilate, quantity: 1 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - vpi-benztropine is recommended for all etiologic groups of parkinsonism - arteriosclerotic, postencephalitic, idiopathic and drug-induced. it can be effective at any stage of the disease, even when a patient has become bedridden. often it is helpful in patients who have become unresponsive to other agents. though parkinsonism is chronic and usually progressive, its symptoms often can be controlled by suitable treatment. therapy is directed toward control of disturbing symptoms to permit maximum integration of function and? minimum discomfort. in non-drug-induced parkinsonism, partial control of symptoms is the usual therapeutic accomplishment. vpi-benztropine is a powerful anticholinergic agent mainly effective in relieving tremor and rigidity. many other troublesome signs and symptoms, including sialorrhea, drooling, mask-like facies, oculogyric crises, speech and writing difficulties, dysphagia, gait disturbances, and pain and insomnia due to cramps and muscle spasm are also ameliorated. extensive muscle rigidity. and spasm, often more disturbing than tremor, may be alleviated. improvement in muscle function relieves many stigmata of parkinsonism. during therapy with vpi-benztropine. the characteristic frozen facies, gait, and posture return toward normal; speech becomes freer; and sustained rigidity; discomfort, and restlessness during sleep usually are relieved. physiotherapy can be applied more easily and may be more effective.

Ireland - English - HPRA (Health Products Regulatory Authority)

merck sharp and dohme limited - benzatropine mesilate - solution for injection - 1 mg milligram